NASDAQ:BNTX

BioNTech Competitors

$132.60
+2.96 (+2.28 %)
(As of 04/14/2021 05:20 PM ET)
Add
Compare
Today's Range
$129.21
Now: $132.60
$132.60
50-Day Range
$90.29
MA: $106.39
$122.14
52-Week Range
$37.00
Now: $132.60
$132.60
Volume3.34 million shs
Average Volume1.98 million shs
Market Capitalization$31.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta-1.74

Competitors

BioNTech (NASDAQ:BNTX) Vs. GILD, MRNA, BIIB, SGEN, TECH, and NVAX

Should you be buying BNTX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to BioNTech, including Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), Seagen (SGEN), Bio-Techne (TECH), and Novavax (NVAX).

Gilead Sciences (NASDAQ:GILD) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Profitability

This table compares Gilead Sciences and BioNTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
BioNTech-250.12%-66.72%-41.73%

Volatility & Risk

Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, suggesting that its stock price is 274% less volatile than the S&P 500.

Earnings and Valuation

This table compares Gilead Sciences and BioNTech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.66$5.39 billion$6.1410.64
BioNTech$121.63 million262.50$-200,540,000.00($0.95)-139.58

Gilead Sciences has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Gilead Sciences and BioNTech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191302.52
BioNTech04302.43

Gilead Sciences currently has a consensus price target of $97.92, suggesting a potential upside of 49.95%. BioNTech has a consensus price target of $105.50, suggesting a potential downside of 20.44%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than BioNTech.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 10.8% of BioNTech shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Gilead Sciences beats BioNTech on 13 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares BioNTech and Moderna's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioNTech-250.12%-66.72%-41.73%
Moderna-242.73%-28.11%-20.31%

Risk & Volatility

BioNTech has a beta of -1.74, meaning that its share price is 274% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.

Valuation & Earnings

This table compares BioNTech and Moderna's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$121.63 million262.50$-200,540,000.00($0.95)-139.58
Moderna$60.21 million1,064.54$-514,020,000.00($1.55)-103.25

BioNTech has higher revenue and earnings than Moderna. BioNTech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for BioNTech and Moderna, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioNTech04302.43
Moderna36902.33

BioNTech presently has a consensus target price of $105.50, suggesting a potential downside of 20.44%. Moderna has a consensus target price of $149.6471, suggesting a potential downside of 6.49%. Given Moderna's higher probable upside, analysts clearly believe Moderna is more favorable than BioNTech.

Institutional & Insider Ownership

10.8% of BioNTech shares are held by institutional investors. Comparatively, 51.2% of Moderna shares are held by institutional investors. 29.2% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Moderna beats BioNTech on 9 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Risk & Volatility

BioNTech has a beta of -1.74, meaning that its share price is 274% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Valuation & Earnings

This table compares BioNTech and Biogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$121.63 million262.50$-200,540,000.00($0.95)-139.58
Biogen$14.38 billion2.82$5.89 billion$33.577.92

Biogen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for BioNTech and Biogen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioNTech04302.43
Biogen5141202.23

BioNTech presently has a consensus target price of $105.50, suggesting a potential downside of 20.44%. Biogen has a consensus target price of $303.5862, suggesting a potential upside of 14.22%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than BioNTech.

Institutional & Insider Ownership

10.8% of BioNTech shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares BioNTech and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioNTech-250.12%-66.72%-41.73%
Biogen35.63%51.00%23.54%

Summary

Biogen beats BioNTech on 12 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Insider & Institutional Ownership

10.8% of BioNTech shares are held by institutional investors. Comparatively, 87.2% of Seagen shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares BioNTech and Seagen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$121.63 million262.50$-200,540,000.00($0.95)-139.58
Seagen$916.71 million28.52$-158,650,000.00($1.33)-108.42

Seagen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Seagen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for BioNTech and Seagen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioNTech04302.43
Seagen161112.63

BioNTech presently has a consensus target price of $105.50, indicating a potential downside of 20.44%. Seagen has a consensus target price of $185.3571, indicating a potential upside of 28.54%. Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than BioNTech.

Profitability

This table compares BioNTech and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioNTech-250.12%-66.72%-41.73%
Seagen25.34%20.46%16.67%

Risk and Volatility

BioNTech has a beta of -1.74, suggesting that its stock price is 274% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Summary

Seagen beats BioNTech on 13 of the 15 factors compared between the two stocks.

Bio-Techne (NASDAQ:TECH) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bio-Techne and BioNTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne03702.70
BioNTech04302.43

Bio-Techne presently has a consensus target price of $367.50, indicating a potential downside of 11.31%. BioNTech has a consensus target price of $105.50, indicating a potential downside of 20.44%. Given Bio-Techne's stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Techne is more favorable than BioNTech.

Volatility and Risk

Bio-Techne has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, suggesting that its stock price is 274% less volatile than the S&P 500.

Earnings & Valuation

This table compares Bio-Techne and BioNTech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million21.76$229.30 million$3.86107.35
BioNTech$121.63 million262.50$-200,540,000.00($0.95)-139.58

Bio-Techne has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 10.8% of BioNTech shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bio-Techne and BioNTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
BioNTech-250.12%-66.72%-41.73%

Summary

Bio-Techne beats BioNTech on 13 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Novavax (NASDAQ:NVAX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for BioNTech and Novavax, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioNTech04302.43
Novavax10602.71

BioNTech presently has a consensus price target of $105.50, indicating a potential downside of 20.44%. Novavax has a consensus price target of $229.6429, indicating a potential upside of 14.06%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than BioNTech.

Volatility & Risk

BioNTech has a beta of -1.74, indicating that its share price is 274% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500.

Valuation & Earnings

This table compares BioNTech and Novavax's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$121.63 million262.50$-200,540,000.00($0.95)-139.58
Novavax$18.66 million796.93$-132,690,000.00($5.80)-34.71

Novavax has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.8% of BioNTech shares are held by institutional investors. Comparatively, 49.9% of Novavax shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares BioNTech and Novavax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioNTech-250.12%-66.72%-41.73%
Novavax-133.10%-1,346.17%-45.85%

Summary

Novavax beats BioNTech on 10 of the 14 factors compared between the two stocks.


BioNTech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.30+0.6%$82.22 billion$22.45 billion67.32
Moderna logo
MRNA
Moderna
1.6$160.03+6.4%$59.96 billion$60.21 million-98.78Insider Selling
Gap Down
Biogen logo
BIIB
Biogen
1.9$265.79+0.2%$40.55 billion$14.38 billion8.80Analyst Report
Analyst Revision
Seagen logo
SGEN
Seagen
1.7$144.20+2.3%$25.54 billion$916.71 million56.77Increase in Short Interest
Bio-Techne logo
TECH
Bio-Techne
2.0$414.38+1.2%$16.08 billion$738.69 million66.30
Novavax logo
NVAX
Novavax
1.4$201.34+3.3%$14.38 billion$18.66 million-38.57News Coverage
argenx logo
ARGX
argenx
1.1$272.78+1.4%$13.80 billion$78.17 million-57.67News Coverage
QIAGEN logo
QGEN
QIAGEN
1.5$51.18+1.7%$11.86 billion$1.53 billion63.19
Repligen logo
RGEN
Repligen
1.5$205.29+3.7%$11.24 billion$270.24 million250.35Analyst Report
News Coverage
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$123.11+1.8%$9.12 billion$289.59 million-37.76News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.05+2.2%$8.73 billion$788.10 million102.21Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$122.37+0.7%$7.46 billion$73.99 million-47.25
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$84.73+6.9%$7.40 billion$10.68 million-46.05
Twist Bioscience logo
TWST
Twist Bioscience
1.2$142.03+0.9%$6.91 billion$90.10 million-37.87Analyst Report
Analyst Revision
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$55.28+2.2%$6.54 billion$26.68 million-25.01
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$45.95+3.2%$6.37 billion$195.99 million287.19Insider Selling
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$42.59+1.9%$5.93 billion$85.07 million-44.83
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$115.68+2.3%$5.78 billionN/A-49.86News Coverage
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$45.55+1.5%$5.74 billion$8.09 million-19.30
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$76.45+2.2%$4.67 billion$20,000.00-5.44Gap Up
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.30+0.0%$4.66 billion$503.70 million33.04
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$29.99+0.5%$4.43 billionN/A-15.62Increase in Short Interest
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.15+4.1%$4.34 billionN/A-15.09Analyst Report
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$72.70+4.5%$3.40 billionN/A-41.78Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$71.68+4.0%$3.32 billion$125.57 million-41.92Insider Selling
News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$34.05+6.1%$2.89 billionN/A0.00News Coverage
Editas Medicine logo
EDIT
Editas Medicine
1.4$41.53+0.3%$2.80 billion$20.53 million-23.87
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$39.79+5.5%$2.76 billion$50.04 million0.00Insider Selling
Vericel logo
VCEL
Vericel
1.1$57.06+0.8%$2.63 billion$117.85 million-5,706,000.00Increase in Short Interest
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.39+6.2%$2.08 billion$31.43 million-5.06
bluebird bio logo
BLUE
bluebird bio
1.8$29.54+4.1%$1.90 billion$44.67 million-2.69
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.83+5.1%$1.84 billionN/A-11.14Decrease in Short Interest
NantKwest logo
NK
NantKwest
1.1$16.76+4.0%$1.83 billion$40,000.00-23.61Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.19+4.9%$1.72 billion$48.83 million-13.41News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.64+3.1%$1.62 billion$102.43 million-19.40
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$74.77+4.1%$1.59 billionN/A-50.52
AlloVir logo
ALVR
AlloVir
1.4$23.56+0.5%$1.54 billionN/A0.00Increase in Short Interest
Immunovant logo
IMVT
Immunovant
1.8$15.91+2.7%$1.52 billionN/A-12.33Increase in Short Interest
News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.34+1.9%$1.47 billion$35.23 million-14.25Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$30.50+0.5%$1.41 billionN/A-17.23
Alector logo
ALEC
Alector
1.3$17.57+0.2%$1.40 billion$21.22 million-7.88
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$36.29+14.4%$1.39 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Gap Down
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$33.18+4.8%$1.36 billionN/A0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Down
Translate Bio logo
TBIO
Translate Bio
1.6$18.66+6.6%$1.31 billion$7.80 million-17.44
Ocugen logo
OCGN
Ocugen
1.1$6.90+2.8%$1.26 billionN/A-4.66Increase in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.85+0.4%$1.16 billionN/A-3.00
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.96+0.9%$1.14 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.70+0.7%$1.12 billion$32.16 million-9.89Analyst Upgrade
Decrease in Short Interest
News Coverage
Cortexyme logo
CRTX
Cortexyme
1.3$36.40+2.0%$1.05 billionN/A-15.17Analyst Downgrade
Curis logo
CRIS
Curis
1.1$11.87+4.2%$1.04 billion$10 million-14.48Increase in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.